Category Archives: Biotechnology

“MARC BEER: THE CAPTAIN OF THE MEDICAL TECHNOLOGY INDUSTRY “

Having graduated from Miami University with a Bachelor of Science situated in Ohio, he has made quite a mark in his career. Marc Beer has delved deeper in the sphere of where technology meets medicine, and this has widely been seen by his indulgence in making wherever company he has been to achieve success, growth and development, a clear indication that not only is he a good leader but the captain of industries in the MedTech industry.

 

On the list of successful entrepreneurs, Marc Beer is on top of it. Recently has been made major news. He has held various positions in the Board of Directors. Genzyme has had Marc Beer as the Vice President of Global Marketing. His major role was being in charge of the launch of the company’s products. He has served in many capacities some of them including sales and marketing executive, Chairman and a member of the Board of directors among other envious positions.

 

Marc Beer CEO and Co-Founder of started Renovia in August 2016 and is the current chairman. With only two years in the industry, it has made impacts. The medical technology is based in Boston, and it helps in creating a difference in people lives by creating devices that help combat pelvic floor disorders. He founded the company with Ramon Iglesias, Yolanda Lorie. His field of expertise is majorly inclined towards the healthcare funding business.

 

Marc Beer has had many work experiences in companies such as ViaCell, a biotechnology company. Under Marc Beer, the company had led a rapid growth with over 300 workers and their specialization if the collection, development, and preservation of the stem cells in the body.

 

With an over 25 years of experience in the commercialization industry of biotechnology, diagnostic industries as well as the pharmaceuticals, Marc Beer has just had a signed deal that is geared towards raising 42 million dollars to help fund a start-up for women health in Renovia Inc. The 42 million dollar funding is considered the B series by Marc Beer and the Renovia company as they have become interested in developing technology that helps women experiencing pelvic disorders floor. This will be done by developing the pelvic disorders treating methods by innovative technology uses.

 

This comes shortly after the Series A funding was used in acquiring another equity for the company. Renovia under Marc Beer has its work geared to bringing new products to the market and thriving in medicine. However, Marc Beer and his team not only have put interest in this major development but also part of the funding has been set aside for the following: Learn more: https://www.benzinga.com/pressreleases/18/08/r12237847/osf-ventures-invests-in-company-developing-solutions-for-pelvic-floor-

 

  • Commercial launches and marketing launches

 

  • Product improvement and development

 

  • Clinical trials for the future

 

Marc Beer & Renovia: Clear For Innovation

Marc Beer, a man of many feats, initially received his Bachelor’s of Science degree from Miami University before delving into the innovation industry. The 54 year old is currently the CEO, co-founder and Chairman of Renovia Inc. with over 25 years of experience in commercialization and evolution in the pharmaceutical, biotechnology, diagnostic and device industries. Prior to his co-founding of Renovia, Marc Beer became the founding CEO of ViaCel during April of 2002. ViaCel is a biotechnology company specializing in the accumulation, conservation, and development of umbilical cord blood stem cells. During a duration of only seven years, he managed to lead the company from its initial commencement to an expeditious expansion and vigorous mercantile coordination. Led by Marc’s leadership, the company expanded to more than 300 employees, and ultimately became public in 2005. The company was conclusively adopted in 2007 by PerkinElmer.

 

Prior to Marc’s role within Genzyme, he acquired various sales and marketing duties in the pharmaceutical and diagnostic sectors of Abbott Laboratories. Additionally, he was formerly a member of the Mass Life Science Board of the Commonwealth of Massachusetts, as he served on the Biotechnology Industry Organization Emerging Companies Section Governing Board. Marc Beer also previously served as a meticulous consultant to OvaScience, which announced their merging with Millendo Therapeutics.

 

During his employment as the CEO of ViaCell, Marc additionally served as a constituent of the board of directors at Erytech Pharma, which is a public bio-pharmaceutical company. Prior to ViaCell, Marc acquired numerous appointments within Genzyme. His most recent position was the Vice President of Global Marketing, where he was accountable for the commercial commencement of various products conveying rare disease societies worldwide. Furthermore, Marc was also the founder and Chairman of the board of directors of the compensation committee of Good Start Genetics, Inc. which was newly acquired by InVitae.

 

Renovia Inc. is set to proceed with with the production of various products associated with pelvic floor disorders. Recently, the company closed a $32 million Series B round, which is the second round of financing for a business through any type of investment, including private equity investors and venture capitalists. One of the early investors in Renovia was Longwood Fund, with their funding contributing to the testing and development of four additional diagnostic and therapeutic products. Longwood Fund is an investing group which primarily focuses on health care. Additionally, the company received $10 million in venture debt.

 

Renovia Inc. is fabricating several diagnostic and therapeutic products aimed at treating pelvic floor disorders such as urinary incontinence. Researchers estimate that this disease affects over 250 million women globally. In April of 2018, the company received its initial Food and Drug Administration approval for Leva, their first product. Learn more: https://gazetteday.com/2018/10/marc-beer-funding-renovia/

 

Marc Beer was nothing less than thrilled and appreciative of the new funding and support. He articulated how he intends to lead Renovia’s development by combining innovation as well as proprietary sensor technologies with a “digital health platform”.

 

The Giving Nature of Jason Hope

In 2010, the entrepreneur Jason Hope donated $500,000 to SENS Foundation to support its research on rejuvenation biotechnologies. This was just one iteration of a huge drive by the global scientific community to fund research in rejuvenation treatments for age-related diseases. SENS is a non-profit founded in 2009 that remains based in California. It concentrates on big human aging-related diseases like Alzheimer’s, Atherosclerosis, and Diabetes. However, these are not its only areas of interest. There are many. Hope deeply feels that the work of SENS will revolutionize the medical world in these areas. Read more about Jason Hope at ideamensch.com

SENS is led by its CEO, Mike Kope. He is convinced that he is driving SENS toward this medical revolution He said Jason Hope’s substantial contribution was instrumental in helping them complete several projects in 2011. His words concerning Hope’s $500,000 donation were seconded by SENS chairman, Peter Thiel. In fact, it was Thiel who hosted the dinner and presentation event where the donation was first officially announced. SENS CSO, Aubrey de Grey stated that one of the biggest of these 2011 projects included research on arteriosclerosis, which is the hardening of the arteries, a leading cause of hypertension in the elderly.

It also contributes to long-sightedness and aging skin. Healthcare is not Hope’s philanthropic concern. Jason Hope is also a frequent financial giver to educational initiatives. Other than SENS, Jason Hope has been involved with such organization as Boys & Girls Club of Metropolitan Phoenix, the Leukemia & Lymphoma Society’s Desert Mountain States Chapter, The Tony Hawk Foundation, The Andre Agassi Foundation, True Colors Fund, The Mark Wahlberg Youth Foundation, Family Health International, Worldwide Orphans Foundation, T Gen Foundation, Teach for America Phoenix, and the International Foundation for Education and Self Help and the Arizona Science Center.

Hope resides in Scottsdale, Arizona with his family. Besides entrepreneurship, has a decided role as a futurist, philanthropist, and investor. He was raised in Tempe, Arizona. He is also extremely interested and involved in both state and national politics. After high school he obtained his undergraduate degree in Finance from Arizona State University, followed by earning an MBA from its W.P. Carey School of Business.

Learn more: http://cityscene.org/jason-hope-the-entrepreneur-from-arizona/

 

Clay Siegall Inspiring Biotech

Clay Siegall began his career in research as a Senior Research Investigator at the Bristol – Myers Squibb Pharmaceutical Research Institute. Dr. Siegall was promoted as Principal Scientist before he bcame a Fellow and Biotechnology Fellow at the National Cancer Institute. Where he began to help launch Seattle Genetics.

Clay Siegall earned his Ph.D. in Gentics and ever since then has made a impact on cancer. Dr. Siegall works to lead the company to great advancements in cancer and ground breaking therapies for cancer patients commuted to important research and research developments to help cancer patients. Dr. Siegall helped Seattle Genetics develop the first antibody drug conjugated including ADCETRIS FDA approved in 2011. ADCETRIS is helping cancer patients in 60 countries. Dr. Siegall known as a leader in new cancer therapies and helps more by fundraisingfor Seattle Genetics raising $1.2 billion.

In result of Seattle Genetics to thrive in advancements in cancer treatments with innovative technology. With the University of Maryland Alumnus of the year for Computer, Math and Natural Science. Dr. Siegall is a very intelligent man with a passion to help others how humbling. Dr. Siegall is ground breaking intelligence to help cancer patients. Also named Paciffic Northwest Ernst and Young Entrepreneur of the year with his scientific achievements. Holding 15 patents with 70 scientific articles published his in depth knowledge in science and medical.

A mentor to young students all around Dr. Siegall inspires more than just his patients. Dr. Siegall strives to help others always putting them first. An honorable man that has knowledge to help others.

Dr. Siegall built Seattle Venice on a foundation of scientific innovation, rigourous research and drug development. Dr. Siegall has a passion for helping others. Clay Siegall is responsible for pioneering alternative drugs for cancer and other deblilitatis genectics disorders. His goal of medication to have a positive impact of those suffering with cancer. Dr. Siegalls role is to create innovative antibody based therapies. To help suffering cancer patients with out nasty side effects

 

Copyright © 2019. Powered by WordPress & Romangie Theme.